[1] Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis[J]. Chin Med J (Engl), 2020, 133(22):2665-2673. DOI: 10.1097/CM9.0000000000001163.
[2] Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)[J]. Br J Dermatol, 2018, 178(3):674-681. DOI: 10.1111/bjd.16050.
[3] Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials[J]. J Am Acad Dermatol, 2020, 82(4):936-945. DOI: 10.1016/j.jaad.2019.11.040.
[4] Galluzzo M, D'Adamio S, Silvaggio D, et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience[J]. Expert Opin Biol Ther, 2020, 20(1):95-104. DOI: 10.1080/14712598.2020. 1684472.
[5] Xie F, Wang R, Zhao ZG, et al. Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: a prospective 12-week follow-up study[J]. J Huazhong Univ Sci Technolog Med Sci, 2017, 37(6):943-947. DOI: 10.1007/s11596-017-1832-7.
[6] Carrera CG, Dapavo P, Malagoli P, et al. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis[J]. J Dermatolog Treat, 2018, 29(5):481-486. DOI: 10.1080/09546634.2017.1395805.
[7] Talamonti M, Galluzzo M, Bernardini N, et al. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study[J]. J Eur Acad Dermatol Venereol, 2018, 32(10):1737-1744. DOI: 10.1111/jdv.15077.
[8] Elewski BE, Baker CS, Crowley JJ, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial[J]. J Eur Acad Dermatol Venereol, 2019, 33(11):2168-2178. DOI: 10.1111/jdv.15793.
[9] D'Angelo S, Cantini F, Ramonda R, et al. Effectiveness of adalimumab for the treatment of psoriatic arthritis: an italian real-life retrospective study[J]. Front Pharmacol, 2019, 10:1497. DOI: 10.3389/fphar.2019.01497.
[10] Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2020, 395(10230):1115-1125. DOI: 10.1016/S0140-6736(20)30265-8.
[11] Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study[J]. J Dermatol, 2018, 45(5):529-539. DOI: 10.1111/1346-8138.14294.
[12] Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study[J]. ACR Open Rheumatol, 2020, 2(1):18-25. DOI: 10.1002/acr2.11097.
[13] Dogra S, Bishnoi A, Narang T, et al. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis[J]. Dermatol Ther, 2018, 31(4):e12611. DOI: 10.1111/dth.12611.
[14] Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change[J]. J Eur Acad Dermatol Venereol, 2021, 35(4):824-834. DOI: 10.1111/jdv.16866.
[15] Pinter A, Gerdes S, Papavassilis C, et al. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis[J]. J Dermatolog Treat, 2020, 31(8):769-775. DOI: 10.1080/09546634. 2019.1626973.
[16] Champs B, Degboé Y, Barnetche T, et al. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials[J]. RMD Open, 2019, 5(1):e000763. DOI: 10.1136/rmdopen-2018-000763.
[17] Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial) [J]. J Invest Dermatol, 2020, 140(1):85-93.e2. DOI: 10.1016/j.jid.2019.07.679.
[18] von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks[J]. J Invest Dermatol, 2019, 139(5):1054-1062. DOI: 10.1016/j.jid.2018.10.042.
[19] Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial[J]. Lancet, 2019, 394(10201):831-839. DOI: 10.1016/S0140-6736(19)31773-8.
[20] Forouzandeh M, Vazquez T, Nouri K, et al. The paradoxical induction of Crohn's disease following treatment of psoriatic arthritis with etanercept[J]. J Drugs Dermatol, 2019, 18(8):832-834.
[21] Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations[J]. J Eur Acad Dermatol Venereol, 2021, 35(2):281-317. DOI: 10.1111/jdv.16926.
[22] Torii H, Nakano M, Yano T, et al. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: results of the SPREAD study[J]. J Dermatol, 2017, 44(5):552-559. DOI: 10.1111/1346-8138.13698.
[23] Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial[J]. Br J Dermatol, 2018, 178(1):114-123. DOI: 10.1111/bjd.15750.
[24] Amschler K, Phillip S, Mohr J, et al. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab[J]. Dermatol Online J, 2020, 26(2):13030/qt11d602x5.
[25] Subedi S, Gong Y, Chen Y, et al. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events[J]. Drug Des Devel Ther, 2019, 13:2491-2502. DOI: 10.2147/DDDT.S200147.
[26] Xia P, Li YH, Liu Z, et al. Recalcitrant paradoxical pustular psoriasis induced by infliximab: two case reports[J]. World J Clin Cases, 2021, 9(15):3655-3661. DOI: 10.12998/wjcc.v9.i15.3655.
[27] Melo FJ, Magina S. Clinical management of anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review[J]. Int J Dermatol, 2018, 57(12):1521-1532. DOI: 10.1111/ijd.14072.
[28] Özkur E, Altunay İK, Leblebici C, et al. Adalimumab-induced scalp psoriasis with severe alopecia[J]. Dermatol Ther, 2019, 32(5):e13033. DOI: 10.1111/dth.13033.
|
